Intrapulmonary shunting causing hypoxaemia in a case of carcinoid syndrome.
A case of metastatic carcinoid syndrome with hypoxaemia is described. The hypoxaemia appeared to be due to intrapulmonary shunting. There was improvement in resting and exercise arterial oxygen saturations following chemotherapy with streptozotocin and 5-fluorouracil. This was followed by a decrease in the tumour bulk which may have led to a reduction in the secretion of the vasodilator products responsible for shunting. Some features of this case suggest that the hypoxaemia might have been due to dilatation of precapillary and capillary vessels of the pulmonary micro-circulation. These features are part of the so-called 'hepatopulmonary syndrome', of which this case appears to represent a less severe form.
Hussain
A
A
Department of Medicine, Wansbeck General Hospital, Northumberland, UK.
Young
E T
ET
Greaves
J D
JD
Hammond
P J
PJ
Hughes
J M
JM
Wallis
S C
SC
Bloom
S R
SR
D000328:Adult; D002276:Carcinoid Tumor / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology / Q000556:secondary; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000860:Hypoxia / Q000209:etiology*; D008113:Liver Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008168:Lung / Q000098:blood supply / Q000503:physiopathology*; D008297:Male; D009382:Neoplasms, Unknown Primary / Q000150:complications* / Q000503:physiopathology; D015282:Octreotide / Q000627:therapeutic use; D011659:Pulmonary Gas Exchange; D013311:Streptozocin / Q000627:therapeutic use
D013311:Streptozocin; D015282:Octreotide; D005472:Fluorouracil